Yahoo · Sep 1, 2026
NorthStrive Biosciences Expands AI-Driven Drug Discovery Program with Yuva Biosciences, Advancing Four Novel AI-Discovered Compounds Toward Lead Nomination for Potential Cardiac Disease and Obesity Therapeutic Applications
Building on positive Phase III results from the parties' AI-driven drug discovery program, the six-month Expansion Program will narrow the four validated compounds toward a nominated lead and designated backup. The Amendment also strengthens the exclusive Cardiac Disease and Obesity field of use and adds a right of first refusal across the broader cardiometabolic field. NEWPORT BEACH, Calif., Sept. 01, 2026 (GLOBE NEWSWIRE) -- NorthStrive Biosciences Inc. ("NorthStrive Biosciences"), a subsidiar
